- Home
- PBYI vs ECF Comparison
PBYI vs ECF Comparison
Compare PBYI & ECF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- ECF
- Stock Information
- Founded
- PBYI 2010
- ECF 1986
- Country
- PBYI United States
- ECF United States
- Employees
- PBYI N/A
- ECF N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- ECF Finance/Investors Services
- Sector
- PBYI Health Care
- ECF Finance
- Exchange
- PBYI Nasdaq
- ECF Nasdaq
- Market Cap
- PBYI 153.2M
- ECF 132.9M
- IPO Year
- PBYI N/A
- ECF N/A
- Fundamental
- Price
- PBYI $2.97
- ECF $9.90
- Analyst Decision
- PBYI Strong Buy
- ECF
- Analyst Count
- PBYI 1
- ECF 0
- Target Price
- PBYI $7.00
- ECF N/A
- AVG Volume (30 Days)
- PBYI 821.3K
- ECF 57.7K
- Earning Date
- PBYI 02-27-2025
- ECF 01-01-0001
- Dividend Yield
- PBYI N/A
- ECF 6.42%
- EPS Growth
- PBYI 492.79
- ECF N/A
- EPS
- PBYI 0.47
- ECF 0.46
- Revenue
- PBYI $243,569,000.00
- ECF N/A
- Revenue This Year
- PBYI N/A
- ECF N/A
- Revenue Next Year
- PBYI N/A
- ECF N/A
- P/E Ratio
- PBYI $6.38
- ECF $17.61
- Revenue Growth
- PBYI 6.30
- ECF N/A
- 52 Week Low
- PBYI $2.23
- ECF $7.02
- 52 Week High
- PBYI $7.73
- ECF $8.91
- Technical
- Relative Strength Index (RSI)
- PBYI 45.95
- ECF 57.04
- Support Level
- PBYI $2.92
- ECF $9.51
- Resistance Level
- PBYI $4.06
- ECF $9.90
- Average True Range (ATR)
- PBYI 0.27
- ECF 0.14
- MACD
- PBYI -0.03
- ECF 0.00
- Stochastic Oscillator
- PBYI 4.39
- ECF 86.67
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About ECF Ellsworth Growth and Income Fund Ltd.
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.